Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 6,481 shares of the company’s stock after buying an additional 451 shares during the period. Daiwa Securities Group Inc.’s holdings in Neurocrine Biosciences were worth $854,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. DSM Capital Partners LLC increased its stake in shares of Neurocrine Biosciences by 15.4% in the third quarter. DSM Capital Partners LLC now owns 1,224,017 shares of the company’s stock valued at $137,702,000 after purchasing an additional 163,747 shares during the period. Braidwell LP increased its stake in shares of Neurocrine Biosciences by 3.7% in the third quarter. Braidwell LP now owns 968,024 shares of the company’s stock valued at $108,903,000 after purchasing an additional 34,662 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of Neurocrine Biosciences by 59.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 692,374 shares of the company’s stock valued at $77,892,000 after purchasing an additional 256,920 shares during the period. Westfield Capital Management Co. LP increased its stake in shares of Neurocrine Biosciences by 73.0% in the third quarter. Westfield Capital Management Co. LP now owns 649,292 shares of the company’s stock valued at $73,045,000 after purchasing an additional 273,952 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Neurocrine Biosciences by 3.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 623,267 shares of the company’s stock valued at $70,118,000 after purchasing an additional 18,334 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. The Goldman Sachs Group raised their price target on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the company a “buy” rating in a research note on Thursday, January 25th. Barclays raised their price objective on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. Oppenheimer reiterated an “outperform” rating and set a $200.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research note on Tuesday. Finally, Mizuho raised their price objective on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday, February 8th. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average target price of $142.38.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Eiry Roberts sold 1,457 shares of Neurocrine Biosciences stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $140.79, for a total transaction of $205,131.03. Following the completion of the sale, the insider now owns 20,832 shares of the company’s stock, valued at approximately $2,932,937.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 5,000 shares of Neurocrine Biosciences stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $145.06, for a total transaction of $725,300.00. Following the completion of the sale, the insider now owns 7,507 shares of the company’s stock, valued at approximately $1,088,965.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eiry Roberts sold 1,457 shares of Neurocrine Biosciences stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $140.79, for a total transaction of $205,131.03. Following the sale, the insider now directly owns 20,832 shares of the company’s stock, valued at approximately $2,932,937.28. The disclosure for this sale can be found here. In the last 90 days, insiders sold 186,994 shares of company stock valued at $25,806,409. Company insiders own 4.40% of the company’s stock.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $138.97 on Thursday. The company has a 50 day moving average price of $136.48 and a 200 day moving average price of $127.62. Neurocrine Biosciences, Inc. has a 52 week low of $89.04 and a 52 week high of $148.37. The firm has a market capitalization of $13.83 billion, a price-to-earnings ratio of 57.43 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The firm had revenue of $515.20 million during the quarter, compared to analyst estimates of $518.52 million. During the same quarter last year, the business posted $0.88 EPS. The company’s revenue was up 25.0% on a year-over-year basis. Equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.